Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/132138
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy
Author: Angus, L.
Leemaqz, S.
Ooi, O.
Cundill, P.
Silberstein, N.
Locke, P.
Zajac, J.D.
Cheung, A.S.
Citation: Endocrine Connections, 2019; 8(7):935-940
Publisher: Bioscientifica
Issue Date: 2019
ISSN: 2049-3614
2049-3614
Statement of
Responsibility: 
Lachlan Angus, Shalem Leemaqz, Olivia Ooi, Pauline Cundill, Nicholas Silberstein, Peter Locke, Jeffrey D Zajac and Ada S Cheung
Abstract: BACKGROUND:Estradiol with or without an antiandrogen (cyproterone acetate or spironolactone) is commonly prescribed in transfeminine individuals who have not had orchidectomy, however there is no evidence to guide optimal treatment choice. OBJECTIVE:We aimed to compare add-on cyproterone acetate versus spironolactone in lowering endogenous testosterone concentrations in transfeminine individuals. DESIGN:Retrospective cross-sectional study. METHODS:We analysed 114 transfeminine individuals who had been on estradiol therapy for >6 months in two gender clinics in Melbourne, Australia. Total testosterone concentrations were compared between three groups; estradiol alone (n=21), estradiol plus cyproterone acetate (n=21) and estradiol plus spironolactone (n=38). Secondary outcomes included serum estradiol concentration, estradiol valerate dose, blood pressure, serum potassium, urea and creatinine. RESULTS:Median age was 27.0 years (22.5, 45.1) and median duration of hormone therapy was 1.5 years (0.9, 2.6), which was not different between groups. On univariate analysis, the cyproterone group had significantly lower total testosterone concentrations (0.8nmol/L (0.6, 1.20)) compared with the spironolactone group (2.0nmol/L (0.9, 9.4), p=0.037) and estradiol alone group (10.5nmol/L (4.9, 17.2), p<0.001), which remained significant (p=0.005) after adjustments for estradiol concentration, dose and age. Serum urea was higher in the spironolactone group compared with the cyproterone group. No differences were observed in total daily estradiol dose, blood pressure, serum estradiol, potassium or creatinine. CONCLUSIONS:The cyproterone group achieved serum total testosterone concentrations in the female reference range. As spironolactone may cause feminisation without inhibition of steroidogenesis, it is unclear which anti-androgen is more effective at feminisation. Further prospective studies are required.
Keywords: Transgender persons; ftranssexualism; gender identity; gender dysphoria; androgens
Rights: © 2019 The authors Published by Bioscientifica Ltd. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.https://doi.org/10.1530/EC-19-0272https://ec.bioscientifica.com
DOI: 10.1530/EC-19-0272
Grant ID: http://purl.org/au-research/grants/nhmrc/1143333
Published version: http://dx.doi.org/10.1530/ec-19-0272
Appears in Collections:Gender Studies and Social Analysis publications

Files in This Item:
File Description SizeFormat 
hdl_132138.pdfPublished version534.22 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.